DISCLAIMER The material in this presentation has been prepared by - PowerPoint PPT Presentation

DISCLAIMER The material in this presentation has been prepared by Virtus Health Limited ABN 80 129 643 492 (“Virtus Health”) and is general background information about Virtus Health’s activities current at the date of this presentation. The information is given in summary form and includes financial and other information and does not purport to be complete. Information in this presentation, including forecast financial information should not be considered as advice or a recommendation to investors or potential investors and does not take into account investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice when deciding if an investment is appropriate. Persons needing advice should consult their stockbroker, solicitor, accountant or other independent financial advisor. The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This presentation does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Certain statements made in this presentation are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Virtus Health Limited’s current expectations, estimates and projections about the industry in which Virtus Health operates, and beliefs and assumptions. Words such as “anticipates”, “expects”, “intends,”, “plans”, “believes”, “seeks”, “estimates”, and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Virtus Health, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Virtus Health cautions investors and potential investors not to place undue reliance on these forward-looking statements, which reflect the view of Virtus Health only as of the date of this presentation. The forward-looking statements made in this presentation relate only to events as of the date on which the statements are made. Virtus Health will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority. A number of figures, amounts, percentages, estimates, calculations of value and fractions in this presentation are subject to the effect of rounding. Accordingly, the actual calculation of these figures may differ from the figures set out in this presentation. In addition, a number of figures have been calculated on the basis of assumed exchange rates, as set out in this presentation. To the maximum extent permitted by law, neither Virtus Health nor its related bodies corporate, directors, officers, employees, agents, contractors, advisers nor any other person, accepts, and each expressly disclaims, any liability, including without limitation any liability arising from fault or negligence, for any errors or misstatements in, or omissions from, this presentation or any direct, indirect or consequential loss arising from the use of this presentation or its contents or otherwise arising in connection with it. 2

Results and Operational Overview FY20

FY20 Financial Results Vi Virtu tus d dem emonstr trates r res esilience i in the m e midst o t of t f the C COVID ID-19 p pandem emic Rev even enue e NPAT a attributable to e to ordinary eq equity ty holders Rep eported EB EBITDA $259m 59m $0.5m 5m $46. 6.2m 2m 1 Down 7.5% Adjusted ted N NPAT $20. $20.6m 2 EPS S No f final d dividen end. Adjusted EB EBITDA Defer erred ed inter terim 0.5 .59 ce cents $66. 6.0m 0m 2 dividen end to b be e paid Adjusted EPS 25.72cps 2 ( FY19: $57.1m) 30 30 Nov ov 2020 2020 No adjustments for COVID-19 subject to trading conditions 1. Virtus adopted AASB16 ‘Leases’ effective 1 July 2019, resulting in an increase to Reported and Adjusted EBITDA of $14.8m and decrease to NPAT of $0.1m for the year ended to 30 June 2020. The comparative period has not been restated, refer to note 12 of full year report and slide 19 for further details. 4 2. Refer to slides 15 and 16.

Results Highlights Balance s e sheet et i improvem emen ent Net debt reduced by Estimated CO COVID-19 i imp mpac act Key i y ite tems $29m to $127m Estimated gross profit loss – Non cash impairment Normalised leverage covenant ($14.6m) charge ($25.0m) reporting agreed with banking group for December 20 Job Keeper / Government Non cash fair value assistance received gains $6.0m Normalised leverage ratio of 2.2x at $7.7m June 20 Funding capacity in excess of $100m 5

COVID-19 Impact and Recovery 8 Months 8 Mo 4 Mo 4 Months 2 Months 2 Mo COVID-19 CO 19 Impact ct 6 Mo 6 Months to Feb 20 20 to June 2 e 20 to July ly 20 20 (compared to pcp) to Dec ec 2 20 (pre-COVID) (during restrictions) (easing of restrictions) Australian fresh Cycles +2.7% +1.4% (15.3%) +23.0% International fresh cycles (3.3%) (2.3%) (35.1%) +18.9% Diagnostics revenue +0.2% +0.2% (14.5%) +14.9% Day Hospital revenue +2.1% +1.5% (15.8%) +37.7% 6

COVID-19 Business Response 01 02 03 Liquidity a and f funding Effective p planning f for r restart Resilie ilience o of ARS d demonstrated sustain inabili ility a achie ieved Tele-health consulting and virtual Following lifting of regulatory suspensions, consultations to build backlog patient activity exceeded prior year Cash management and preservation comparative activity, reaffirming the strategies implemented. demand for ARS. Recruited new specialist surgeons and increased volume from existing surgeons Agreement reached with banking partners Robust infection control protocols have to to Day Hospitals to relevant normalisations to covenant date managed the safety of patients, staff calculations for the reporting to and doctors. December 2020. Support from doctors and staff IVF highlighted as essential service in Not required to raise equity in a Victoria lockdown and services continue at Higher demand and lower supply of PPE discounted market. 75% capacity. mitigated by working with suppliers and clinical teams to limit disruption to daily operations. 7

Segment Performance

Australian Operations Australian s segm gmen ent rev even enue e down wn 6 6.2% o on pcp to $208 $208.6m 1) (FY19: $74.9m (1) Austr tralian s seg egment t EB EBITDA u up 22.7% to $ 19: $ $61.1m 1m) Pre e AASB 1 16 “Le Leases” a adoption, A Austr tralian s seg egment t EB EBITDA u up 3.4% to $ $63.2m (FY19: 19: $ $61.1m 1m) June/ une/July 2020 D 0 Diagnostics s June/ une/July 2 20 A Activi vity demonstrates t es the he June/ une/July 2 2020 0 Day H Hospi spital rev even enue e up 1 p 14.9% 9% o on pcp cp resi silien ence o e of I IVF F as a non-discretionary rev even enue e up 3 p 37.7% 7% o on pcp cp service: Australian fresh IVF cycles up Virtus’ capability in genetics 23% on pcp Hospital efficiencies optimized creates a strong position to and utilisation increased by capture growth in ARS as families Virtus A us Australia out utper erforms c cycle e recruitment of new surgeons and look to avoid passing potential vo volum ume i e in a available m e market a across F s FY20 increased volumes from existing genetic disease to their children (available market down 5.3% on pcp. surgeons Virtus down 4.4%) 1. $11.8m positive impact on EBITDA arising from the adoption of AASB 16 ‘Leases’ 9

Danish Operations Danish r rev even enue d e down wn 5 5.1% o on pcp to to DKK4 KK49.9m Danish E EBITDA d down wn b by 2 28.7% o on pcp to D DKK11. 11.6m 6m ( (FY19: 19:DKK16. 16.2) 2) Medi edical t tea eam s stability New ew l local l leader ershi ship a and nd Minimal shutdown a and ref efresh eshed ed growth s strateg egy early ea ly mobi bilisa sation Recruitment of additional medical capacity plus a new w An exper perien enced ed N Nationa nal C Clinical D Direc ector Strong marketing and planning Medi edical D Direc ector f for Aagaard appointed in January 2020 resulted in Virtus s Dani nish c sh clinics s facilitated improved activity and being t the fi first i in D Denmark to fully revenues in H2 Growth strategy includes a foc ocus on on re-mobilise following shutdown posi sitioning V Virtus s Dani nish C sh Clinics a s as a with subsequent high demand Europe pean h n hub b for Fertility patients The analysis above excludes the impact on EBITDA on adoption of AASB 16 “Leases” 10